Why the study?
Early identification of reliable biochemical markers is needed in PCOS to ensure timely diagnosis and management, preventing long-term complications such as type 2 diabetes and cardiovascular disease.
Population
91 women including 49 PCOS cases and 42 age-matched controls (mean age 25.5 ± 5.3 years)
Comparison
PCOS cases vs age-matched controls
Design
Retrospective study
Key result
Elevated serum anti-Müllerian hormone was a strong predictor of polycystic ovary syndrome (OR 1.45), alongside fasting blood sugar and luteinizing hormone.
Authors
Loading...
AMH-insulin resistance association in adolescent PCOS is hypothesis-generating; leaves open whether it aids early cardiometabolic risk stratification.
Case-Control (n=91)
No
Odds Ratio: 1.45
p-value: p=<0.001
AMH, LH, and FBS are robust markers for diagnosing PCOS, correlating with insulin resistance and lipid alterations to support early risk stratification.
Kumari et al. (2025) conducted a case-control in Polycystic Ovary Syndrome (PCOS) (n=91). Elevated serum Anti-Müllerian Hormone (AMH) vs. Lower serum AMH levels was evaluated on Polycystic Ovary Syndrome (PCOS) diagnosis (OR 1.45, p=<0.001). Elevated serum anti-Müllerian hormone was a strong predictor of polycystic ovary syndrome (OR 1.45), alongside fasting blood sugar and luteinizing hormone.